SCHEMBL1373290

SCHEMBL1373290

NCCCCC(N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 3/20 0.59
NPY1R P25929 2/20 0.59
NPY2R P49146 2/20 0.59
ERAP2 Q6P179 1/20 0.55
LNPEP Q9UIQ6 1/20 0.55
NAALAD2 Q9Y3Q0 1/20 0.52
MME P08473 3/20 0.52
MMP2 P08253 1/20 0.52
ACE P12821 3/20 0.51
CPA1 P15085 1/20 0.51
ACE2 Q9BYF1 1/20 0.51
CHRNA1 P02708 1/20 0.50
CHRNG P07510 1/20 0.50
CHRNB1 P11230 1/20 0.50
CHRND Q07001 1/20 0.50
SLC7A5 Q01650 1/20 0.50
NPPA P01160 1/20 0.50
ECE1 P42892 1/20 0.50
NTSR2 O95665 1/20 0.49
NTSR1 P30989 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15011504 1.00 NPY4R (0.59) NPY4RNPY1RNPY2RERAP2LNPEP
SCHEMBL1373292 1.00 NPY4R (0.59) NPY4RNPY1RNPY2RERAP2LNPEP
SCHEMBL30179294 0.97 NPY4R (0.63) NPY4RNPY1RNPY2RERAP2LNPEP
Acetic Acid SCHEMBL28326516 0.96 NPY4R (0.59) NPY4RNPY1RNPY2RERAP2LNPEP
Acetic Acid SCHEMBL20489334 0.96 NPY4R (0.59) NPY4RNPY1RNPY2RERAP2LNPEP
SCHEMBL30772332 0.96 NPY4R (0.64) NPY4RNPY1RNPY2RERAP2LNPEP
SCHEMBL4655518 0.96 NPY1R (0.58) NPY4RNPY1RNPY2RERAP2LNPEP
Lysylphenylalanyltyrosine SCHEMBL14583994 0.94 NPY1R (0.60) NPY4RNPY1RNPY2RMMEMMP2
Lysylphenylalanyltyrosine SCHEMBL4283579 0.94 NPY1R (0.60) NPY4RNPY1RNPY2RMMEMMP2
SCHEMBL30179482 0.94 NPY1R (0.60) NPY4RNPY1RNPY2RMMEMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110418837-B Culture medium comprising oligopeptides 赢创运营有限公司 2024-04-02 CN disclosed
EP-3372671-B1 CULTURE MEDIUM COMPRISING OLGOPEPTIDES EVONIK OPERATIONS GMBH (DE) 2021-11-03 EP disclosed
CN-110418837-A Culture medium comprising oligopeptides EVONIK TECHNOCHEMIE GMBH 2019-11-05 CN disclosed
WO-2018162346-A1 CULTURE MEDIUM COMPRISING OLIGOPEPTIDES EVONIK TECHNOCHEMIE GMBH (DE) 2018-09-13 WO disclosed
EP-3372671-A1 CULTURE MEDIUM COMPRISING OLGOPEPTIDES Evonik Technochemie GmbH (DE) 2018-09-12 EP disclosed
US-20160263235-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC (CA) 2016-09-15 US disclosed
EP-2794663-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF Angiochem Inc. (CA) 2014-10-29 EP disclosed
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2011-11-24 US disclosed
WO-2010063124-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263235-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF VIP, SLC1A5, SLC47A1 NPY4R 39/4885NPY1R 22/4885NPY2R 94/4885
US-20110288011-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF VIP, SLC1A5, SLC47A1 NPY4R 39/4885NPY1R 22/4885NPY2R 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.